Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended peginterferon alfa-2a plus ribavirin dosing study in HIV/HCV coinfected adults without week-4 undetectable HCV RNA
2006-005940-99Phase 4Active
- Sponsor
- vicente soriano
- Start
- Sep 2012
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a, ribavirin and epoetin beta in hepatitis C virus infection (2 arms), sponsored by vicente soriano. Primary endpoint: Sustained virological response. Started Sep 2012; status: active.
02
Drugs
peginterferon alfa-2aribavirinepoetin beta
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-005940-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005940-99.